Vernakalant - Wikipedia
Vernakalant, sold under the brand name Brinavess, is a class III antiarrhythmic drug for the acute conversion of atrial fibrillation, a kind of irregular heartbeat, in form of an intravenous infusion. It has been approved for use in the European Union and the United Kingdom since 2010.
Vernakalant: Uses, Interactions, Mechanism of Action - DrugBank …
2008年3月19日 · Vernakalant is an antiarrhythmic medication used to treat patients with atrial fibrillation. Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
抗心律失常药物治疗的新药热点 - 中华心律失常学杂志
维纳卡兰(vernakalant)属于Kv1.5介导的I Kur 抑制剂，目前已应用于临床。 维纳卡兰可特异性阻断心房 I Kur ，Na + 峰值电流( I Na )和瞬时外向钾电流 I to ，通过抑制心房的复极过程，延长心房肌的有效不应期。
Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the ...
Vernakalant is a relatively new anti-arrhythmic drug that showed efficacy and safety in recent-onset atrial fibrillation. Vernakalant is indicated in atrial fibrillation (⩽7 days) in patients with no heart disease (class I, level A) or in patients with mild or …
Efficacy and safety of vernakalant for cardioversion of recent …
2022年3月3日 · Vernakalant has been generally considered as selectively blocking atrial-specific IKur and IKAch rapid cardioversion of AF. Considering the importance of maintaining sinus rhythm in the treatment of AF, we hope this systematic review can provide the health care workers with more high-quality evidence to choose vernakalant for patients with ...
Vernakalant: a new drug to treat patients with acute onset atrial ...
Vernakalant is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific channels: the Kv1.5 channel which carries IK (ur), and the Kir3.1/3.4 channel which carries IK (Ach). Vernakalant can also work to block Ito, late Ina, with minor blockade of IKr currents.
房颤快速复律的新星——Vernakalant - 分析测试百科网
Vernakalant禁用于低血压（收缩压＜100mmHg），30天内新发的ACS，NYHA心功能III-IV级，主动脉重度狭窄和QTc间期延长（＞440 ms）的患者。 由于增加低血压发生率，Vernakalant慎用于NYHA心功能I-II级的房颤患者。
Vernakalant - Nature Reviews Drug Discovery
2010年12月1日 · Vernakalant (Fig. 1) is an anti-arrhythmic agent that affects cardiac Na + and K + currents, including the atrial-selective currents IKur and IK,ACh (Refs 4, 5, 6).
Vernakalant - an overview | ScienceDirect Topics
Vernakalant is an inhibitor of several ion channels, in particular, it exerts a blocking action on the K+, Na+, and Ca++ channels at the atrial level, whereby it prolongs the refractoriness time. It is effective in the pharmacologic cardioversion of short-term atrial fibrillation, while it is ineffective in flutter and persistent atrial ...
Vernakalant hydrochloride for the treatment of atrial fibrillation ...
Vernakalant is an intravenous anti-arrhythmic drug available in Europe, Canada and some countries in Asia for the restoration of sinus rhythm in acute onset atrial fibrillation. Currently, it is not available in USA because the US FDA have ongoing concerns about its safety.